Funding Round
SetPoint Medical Raises $140M Series D+ for Neuroimmune Modulation
SetPoint Medical8/11/2025·08/11/25🌐 USA
Summary
SetPoint Medical raised $140M Series D+ for implantable neuroimmune modulation therapy for rheumatoid arthritis and other autoimmune diseases.
Why it matters
SetPoint Medical's $140M Series D+ funds commercial scaling of their vagus nerve stimulator for rheumatoid arthritis and IBD, the first bioelectronic medicine approved for an autoimmune indication. The raise cements bioelectronics as a credible therapeutic modality beyond neurology.
#BCI#Bioelectronic Medicine#Industry#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in